ADCETRIS (brentuximab vedotin, Takeda) has been listed on the Pharmaceutical Benefits Scheme (PBS) for first-line treatment, in combination with chemotherapy, in people with CD30 Stage III or Stage IV Hodgkin lymphoma.
Under the PBS criteria, Adcetris must be used in combination with at least doxorubicin and vinblastine, with dacarbazine a further potential addition.
"This PBS listing introduces another front-line treatment option for Australians diagnosed with advanced-stage Hodgkin lymphoma, expanding the choices available to clinicians and reflecting our commitment to providing access to innovative therapies and to supporting patients, families and the clinical community," said Dr Tania Kew, Medical Director Oceania (ANZ) for Takeda.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Nov 25
